Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April 12-14.

Slides:



Advertisements
Similar presentations
Setting a Research Agenda: Human Resources and Social Development.
Advertisements

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.
Background information
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.
E5 Experiences in Japan Examples with unfavorable outcome How can we improve? Masuhiro Kato, PhD Chair, EFPIA Japan Technical Subcommittee (AstraZeneca.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Frank Moore, Health Administrator/Mental Health Director Linn County Department of Health Services OSHE Panel Discussion: Improving Mental Healthcare Delivery.
KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases.
Cancer Clinical Trials:
Global Health Program Guiding Principles April 2002.
Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.
David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.
Supporting research and patient outreach for FacioScapuloHumeral Muscular Dystrophy (FSHD), one of the most common forms of muscular dystrophy. Progress.
Translational Research and Patient Safety in Europe TRANSFoRm: Requirements analysis for the learning healthcare system.
1 NATIONAL ADVISORY COUNCIL ON HEALTHCARE RESEARCH AND QUALITY Subcommittee on Quality Measures for Children's Healthcare in Medicaid and CHIP Overview.
Copyright © 2014 Oracle and/or its affiliates. All rights reserved. | Oracle Health Sciences Global Business Unit Strategy Steve Rosenberg Senior Vice.
05/09/2015www.ecrin.org1 European Clinical Research Infrastructures Network
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Creating a Model for Systemic Change: The ASD Early STEP Project Shannon Haworth, MA, Donna Gilles, Ed.D., Deana Buck, MA, Parthy Dinora, Ph.D., Dana Yarbrough,
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Summary About me & AMRC About the EU Clinical Trials Regulation – what’s new Implementation timeline What does this mean for UK ethicists?
Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.
Director, DG RTD, Directorate International Cooperation
Welcome Rebecca Wood Chief Executive. Welcome Alzheimer’s Research UK.
A National Approach to Cancer Control in Canada Remarks by Jeff Lozon, Chair Canadian Partnership Against Cancer.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
2010 NIAMS Scientific Retreat Comparative Effectiveness Research Institute of Medicine Priorities Functional Limitations & Disabilities Endocrinology &
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Global Ministerial Forum on Research for Health Bamako Mali, November 2008 Objectives, themes and processes Susan Jupp Head, External Relations Global.
Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,
Developing a National Critical Care Clinical Research Network: what’s in it for trainees? Paul Dark Associate Professor, Faculty of Medical and Human Sciences,
Chapter Quality Network (CQN) Asthma Pilot Project Our Now and Our Future James C. Wiley, MD, FAAP CQN Chapter Physician Leader Alabama Chapter-AAP President.
TM Centers for Disease Control and Prevention National Center on Birth Defects and Developmental Disabilities Centers for Disease Control and Prevention.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
The European Innovation Partnership for asthma: an opportunity for change Samantha Walker PhD, Asthma UK Project Coordinator, EARIP (European Asthma Research.
UIPS Utrecht Institute for Pharmaceutical Sciences Priority Medicines for Europe and the World: Cross-cutting themes Hubert G. Leufkens.
Nursing Process: The Foundation for Safe and Effective Care Chapter 5.
Topic 3A SEMANTIC INTEROPERABILITY: REUSE OF EHR DATA Mats Sundgren.
Evan Lee, MD, MBA Executive Director Global Health Partnership (USA) September 2012.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
Nevada State Innovation Model (SIM) Clinical Outcomes and Quality Workgroup May 06,
Take-home messages. Planning & collaboration in emergency management Emergencies are not only possible, but inevitable Emergency planning should include.
PHDSC Privacy, Security, and Data Sharing Committee Letter to Governors.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Countdown to 2015: tracking progress in child survival. Dr Francisco Songane, Director, Partnership for Maternal, Newborn and Child Health 14 December.
Patients access to investigational drugs Steinar Aamdal Dept. of Clinical Cancer Research Oslo University Hospital.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
IncoNet EaP is a project funded under the 7th European Framework Programme for research - Project number EU-Eastern Partnership STI Cooperation.
1 Outcome of the 4 th Global Animal Health Conference (GAHC) June 2015 Bettye K. Walters, DVM US Food and Drug Administration
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.
A capacity building programme for patient representatives
MEP Interest Group on Brain, Mind and Pain
Health Technology Assessment
Evidence-based Medicine
Lessons Learned Through HBD: The Regulator’s View - US FDA
Research benefits of NHS IT Programmes
Experimental Medicine Challenge Grants Round 3
Trial Funding and Engagement: The NIH Sponsored CTSA Program
There are more than 7,000 single-gene diseases
Ethical Considerations for Pediatric Clinical Investigations
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Introduction: leaving care
IMI – an opportunity to implement research for patients and with patients Catherine Brett European Parliament Interest Group on Allergy and Asthma
The Norwalk Story: How one community is using the Ages and Stages Questionnaires (ASQ®) to build a system for developmental screening for young children.
Partnership for Research and Innovation in the Health System (PRIHS) /2020 Sean Dewitt, Program Manager, Health, Alberta Innovates Marc Leduc,
Presentation transcript:

Safe and Effective Medicine for Children Daring to be Rare, BIOTECanada Panel 2015 CADTH Symposium Saskatoon, April 12-14

MICYRN Federal non-profit society (2011) Joins 20 maternal – child health research institutions and disease networks Collaboration on research infrastructure (ethics review, data management…) to reduce duplication of effort and harmonize processes Prime focus to reduce barriers to multi-jurisdictional research (national, international) Focus on rare diseases

Why a focus on Rare Diseases? Affect < 1/2000 individuals, 1/12 = 2.7 M Canadians Around 7,000 disorders 80% genetic origin 75% present in childhood

Global Objectives 2020:  diagnosis of most rare diseases  200 new therapies New therapies

MICYRN & Rare Diseases 1.Diagnosis: - Advisory to Orpha-net - Rare Diseases Models & Mechanisms Network - Patient Registries/Harmonization 2.Therapies: - National plan for pediatric clinical trials research infrastructure (KIDSCAN) - Collaboration in Industry-instigated PCTRI and EU Research Infrastructure 2020 Roadmap initiatives

*

RD Models and Mechanisms Network GeneX $25K $2.3 M Catalyst Grant

RDMM

Understanding Pathogenesis: Patient Registries Health Canada Industry Investigator trials MOH-HTA Patients Foundations Care providers Numbers: incidence, prevalence Natural history Patient outcome measures Surrogate measures pre-debility Stratification of disease Post authorization monitoring beyond safety Adaptive authorization MICYRN Clinical Research Informatics platform supports Registries; International harmonization projects between rare disease registries

Clinical trials: methodological Challenges - Small populations, original methods - Rare disease, recruitment at multiple sites - Identifying age –appropriate clinical outcomes - Age –appropriate measurements - QOL questionnaires and validation - Age –appropriate interventions - Doses, routes….. - Blood draws in pediatric patients/ invasive tests - When “2 table spoons” are already too much - “Will it hurt?” - Inclusion in multiple trials - Complex regulation, multiple REB, contracts,..

Children take medications, many of which have not been proven safe and effective for their use. Children respond to medications differently from adults; thus, medicines must be studied in children and formulated for children. Studying medicines in children is always possible and in their best interests. In the United States and the European Union, pediatric medicines research is encouraged, required and monitored in ways that offer lessons for Canada. Pediatric medicines research is a Canadian strength, but it requires reinforcement and sustained capacity and infrastructure to realize its full potential. Council of Canadian Academies report, Sept 2014

KIDSCAN: a Proposal to develop a Canadian Coordinating and Advisory Network and Infrastructure to Ensure Best Therapies for Children

A national infrastructure coordinating and enabling pediatric clinical trials. New clinical trial methodologies, developed with patients and other stakeholders, will provide regulators and reimbursors with the best evidence to determine drug authorization and access. Coordinated development of registries of patient populations with sharing of harmonized phenotype and genotype data both nationally and internationally, will capture the natural history of disorders, establish markers of disease and disability, and determine the impact of interventions.